NEW YORK, April 19, 2022 (GLOBE NEWSWIRE) — According to recent industry analysis on the US Respiratory Syncytial Virus Vaccine Market by Persistence Market Research, a leading market research firm, the industry is projected be valued at US$320.3 million in 2022, and is expected to grow at a CAGR of 18.2% over the next ten years. The demand for RSV vaccines in the United States is expected to increase significantly due to the large number of ongoing clinical trials and a strong pipeline of products showing promising results.
Over the past 10 years, considerable progress has been made in the development of a vaccine against RSV. The major manufacturers of these vaccines use monoclonal antibodies to induce passive immunization in infants. Currently, approximately 17 new RSV vaccines are in clinical development, including live attenuated, vector-based, particle-based and subunit-based vaccines.
Currently, key market players such as GSK, Janssen, Moderna, and Pfizer have ongoing global phase III trials for RSV vaccines, which represents an excellent opportunity for industrial growth as well as the launch of these products on the market. market in the future. Increased funding from government agencies plays a vital role in stimulating market demand by supporting R&D activities in the country.
Request for copy of report: https://www.persistencemarketresearch.com/samples/33045
Thus, active participation of key players in clinical trials and government financial assistance will help drive the respiratory syncytial virus vaccine market in the United States to reach a valuation of $1.7 billion by the end of 2032.
Key insights from market research
- By drug, nirsevimab (MEDI8897) is expected to dominate the US market with a valuation of $406.6 million by 2032.
- Based on distribution channel, institutional sales are expected to dominate the market with revenue worth $754.3 million by 2032.
“The growing number of products in the clinical pipeline is expected to drive the U.S. respiratory syncytial virus vaccine market,” says an analyst at Persistence Market Research.
Custom report request as needed: https://www.persistencemarketresearch.com/request-customization/33045
Leading Respiratory Syncytial Virus (RSV) Vaccine Manufacturers Focus on Inorganic Growth by Conducting RSV Vaccine Clinical Trials to Expand Market Share and Presence, While Strengthening Capabilities with Broader Offerings to meet growing market demand.
This approach helps in the development of cost-effective vaccines with superior efficacy and performance, which is expected to drive the market growth over the forecast period (2022 to 2032).
Get full access to the report: https://www.persistencemarketresearch.com/checkout/33045
- In February 2022, GlaxoSmithKline plc announced a voluntary pause in the recruitment and vaccination of trials evaluating a potential maternal RSV vaccine candidate in pregnant women.
What does the report cover?
Persistence Market Research offers unique perspective and actionable insights on the US Respiratory Syncytial Virus Vaccines Market in its latest study, presenting a historical demand assessment from 2017 to 2021 and projections for 2022 to 2032.
The research study is based on the drug (Palivizumab, RSVpreF PF06928316, RSVPreF3 OA (GSK3844766A), mRNA-1345, mRNA-1345, Janssen RSV Vaccine, ResVax, Nirsevimab (MEDI8897) and MVA-BN RSV) and the channel of distribution (institutional sales, retail sales and online sales), in the United States
About Persistence Market Research:
Persistence Market Research (PMR), as a third-party research organization, operates through a proprietary fusion of market research and data analytics to help businesses soar high, regardless of the turbulence encountered due to the financial/natural crises.
Persistence Market Research is always ahead of its time. In other words, he presents market solutions by putting himself in the shoes of the companies/customers long before they themselves have a boost in the market. The proactive approach followed by the experts of Persistence Market Research helps companies/clients to get their hands on technical-commercial information in advance, so that the subsequent action plan can be simplified on their part.
Persistence Market Research
USA Sales Office:
305 Broadway, 7th Floor
New York, NY 10007
United States – Canada Toll Free: 800-961-0353
Email: [email protected]
Visit our website: https://www.persistencemarketresearch.com